Antipsychotics

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.

Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.

People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.

Withholding antipsychotics may be beneficial for memory, the researchers write.

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Peter Lehmann reviews the contribution of antipsychotics to suicide and depression in schizophrenia in the current International Journal of Psychotherapy.  Publications about the intrinsic effects of...

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.